Scientists Discover a New Blood Pressure-Lowering Peptide Hiding in the Renin-Angiotensin System

The researchers used an extensive array of techniques: mass spectrometry (MALDI/TOF/TOF and LC-MS/MS) to identify and confirm the peptide in blood; isolated blood vessels and perfused hearts to test cardiovascular effects; isolated cardiomyocytes for contractility measurements; blood pressure recording in freely moving normotensive and hypertensive rats; echocardiography; central brain administration; cell culture experiments with receptor-transfected cells; and knockout mice lacking Mas, MrgD, or AT2 receptors to determine which receptors mediate the peptide's effects.

The renin-angiotensin system is one of the most important peptide cascades in human physiology, controlling blood pressure, fluid balance, and cardiovascular function. Discovering a completely new bioactive peptide within this well-studied system is remarkable. Ala-(1-5) lowers blood pressure through mechanisms distinct from existing RAS peptides, potentially opening new therapeutic avenues for hypertension that target a previously unknown pathway.

The renin-angiotensin system was thought to be well understood, with drugs targeting it (ACE inhibitors, ARBs) already among the most prescribed medications worldwide. Finding an entirely new bioactive peptide within this cascade — one with distinct cardiovascular effects — shows that even well-studied biological systems can harbor surprises. This discovery expands the 'protective arm' of the renin-angiotensin system and could eventually lead to novel hypertension therapies that work differently from current medications.

This is primarily animal and cell-based research. While Ala-(1-5) was detected in human blood, all functional studies were conducted in rodents and cell lines. The blood pressure-lowering effects, cardiovascular actions, and receptor mechanisms need to be confirmed in humans before any clinical relevance can be established.